Vascular effects of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA): the MARINA study

ISRCTN ISRCTN66664610
DOI https://doi.org/10.1186/ISRCTN66664610
Secondary identifying numbers N2041
Submission date
25/09/2008
Registration date
17/12/2008
Last edited
15/04/2014
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Study website

Contact information

Prof Thomas Sanders
Scientific

Nutritional Science Division
4th Floor, Franklin-Wilkins Building
150 Stamford Street
London
SE1 9NH
United Kingdom

Phone +44 (0)20 7848 4273
Email tom.sanders@kcl.ac.uk

Study information

Study designParallel design, double-blind placebo controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Other
Study typeTreatment
Participant information sheet Patient information material can be found at http://www.medscinet.net/marina/patientinfo.aspx
Scientific titleInfluence of increasing intakes of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on vascular function and risk factors for cardiovascular disease
Study acronymMARINA
Study objectivesIncreasing the intake of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) will have favourable effects on heart-rate variability, endothelial function, arterial stiffness, blood pressure and these effects will be dose-related.
Ethics approval(s)St. Thomas' Hospital Research Ethics Committee, 25/02/2008, ref: 08/H0802/3
Health condition(s) or problem(s) studiedCardiovascular disease
InterventionThis is a dietary intervention involving supplementation with encapsulated (n-3) polyunsaturated fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), at three different doses (0.45, 0.9 and 1.8 g/d), compared with olive oil (BP specification) placebo. The duration of the intervention is 13 months. One month run-in on placebo and 12 months on one of four treatments.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Applicable
Drug / device / biological / vaccine name(s)Eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), polyunsaturated fatty acids
Primary outcome measureA change in endothelial function measured by the flow-mediated dilatation technique and ambulatory blood pressure, measured at baseline and 12 months.
Secondary outcome measures1. Heart rate variability, measured at baseline, 6 months and 12 months
2. Arterial stiffness, measured at baseline and 12 months
3. Endothelial progenitor cell number, measured at baseline, 6 months and 12 months
4. Serum lipids, measured at baseline, 6 months and 12 months
5. C-reactive protein, measured at baseline, 6 months and 12 months
Overall study start date01/06/2008
Completion date31/12/2010

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants360
Key inclusion criteriaMen and women, aged 45 - 70 years
Key exclusion criteria1. A reported history of angina, myocardial infarction or stroke
2. Clinical history of cancer (excluding basal cell carcinoma) in the past five years
3. Uncontrolled type 2 diabetes mellitus (fasting plasma glucose greater than 7 mmol/L)
4. Type 1 diabetes mellitus
5. Chronic renal, liver or inflammatory bowel disease
6. Current cigarette smoker
7. History of substance abuse or alcoholism (previous weekly alcohol intake greater than 60 units/men or 50 units/women)
8. Current self-reported weekly alcohol intake not exceeding 21 units for women and 28 for men
9. Currently pregnant, planning pregnancy or having had a baby in the last 12 months (there are no hazards from the EPA or DHA with regard to pregnancy outcome)
10. Allergy or intolerance to any component of study capsules
11. Unwilling to follow the protocol and/or give informed consent
12. Unwilling to refrain from use of dietary supplements including other sources of fish oil (e.g. cod liver oil)
13. Unwilling to restrict consumption of oily fish
14. Weight change of greater than 3 kg in preceding 2 months
15. Body mass index less than 20 and greater than 35 kg/m^2
16. Subjects with an overall risk of cardiovascular disease over the next ten years of greater than 20% who have untreated high blood pressure or raised cholesterol (subjects who are on stable medication for blood pressure or serum cholesterol [statins] will be included)
Date of first enrolment01/06/2008
Date of final enrolment31/12/2010

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Nutritional Science Division
London
SE1 9NH
United Kingdom

Sponsor information

King's College London (UK)
University/education

Franklin-Wilkins Building
150 Stamford Street
LONDON
SE1 9NH
England
United Kingdom

Phone +44 (0)20 7848 4273
Email tom.sanders@kcl.ac.uk
Website http://www.kcl.ac.uk
ROR logo "ROR" https://ror.org/0220mzb33

Funders

Funder type

Government

Food Standards Agency (UK) (ref: N2041)
Private sector organisation / Other non-profit organizations
Alternative name(s)
The Food Standards Agency, FSA
Location
United Kingdom

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/10/2011 Yes No
Results article genetic analysis results 01/07/2013 Yes No
Results article results 01/03/2014 Yes No